Back
ESC Premium Access

Vericiguat and health status outcomes in heart failure with reduced ejection fraction: Insights from the VICTORIA trial

Session: Congress committee e-posters choice in heart failure
Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)
Speaker: Professor J. Butler (Dallas, US)
Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

About the speaker

Professor Javed Butler

Baylor Scott and White Health, Dallas (United States of America)
101 presentations
10 followers

46 more presentations in this session

Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes

Speaker: Doctor A. Sharma (Montreal, CA)

Access
Abstract
Slides
Thumbnail

SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis

Speaker: Doctor V. Razuk (New York, US)

Access
Abstract
Slides
Thumbnail

Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis

Speaker: Doctor G. Gager (Vienna, AT)

Access
Abstract
Slides
Thumbnail

Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin

Speaker: Doctor J. Kolwelter (Erlangen, DE)

Access
Abstract
Slides
Thumbnail

Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial

Speaker: Doctor M. Senni (Bergamo, IT)

Access
Abstract
Slides
Thumbnail

Access the full session

Congress committee e-posters choice in heart failure

Speakers: Professor J. Butler, Doctor A. Sharma, Doctor V. Razuk, Doctor G. Gager, Doctor J. Kolwelter...
Access
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb